Nihon Kohden, a global leader in medical device innovation for high-precision patient monitoring and diagnostics, announced the acquisition of a 71.4% stake in NeuroAdvanced Corp., the parent company of Ad-Tech Medical Instrument Corporation (Ad-Tech), a trusted provider of specialized electrodes for epilepsy treatment and neurodiagnostic procedures. The move further solidifies Nihon Kohden’s position as an industry leader by combining its established expertise in EEG systems with Ad-Tech’s specialized intracranial electrodes—strengthening the company’s ability to address complex neurological conditions, including drug-resistant epilepsy.
By combining its six decades of deep-rooted expertise in neurology diagnostics with Ad-Tech’s best-in-class consumables, Nihon Kohden is primed to deliver even more impactful and integrated care. With both companies already present in a majority of the top 50 U.S. hospitals, the acquisition creates added synergy and ease of adoption for clinicians and hospital systems nationwide.
“This acquisition represents a pivotal step in advancing critical solutions for epilepsy care,” said Roy Sakai, President of Nihon Kohden America. “By uniting our strengths, we’re enhancing our ability to provide end-to-end support for epilepsy—from accurate diagnosis to advanced interventions.”
Also Read: HealthTap Enters DME Market, Partners with Aeroflow
Ad-Tech’s electrode devices—used in long-term EEG monitoring, brain mapping, SEEG and brain stimulation—are instrumental in treating patients with intractable epilepsy and other neurological disorders. Since its founding in 1983, Ad-Tech has built a worldwide presence, with products approved in over 60 countries, including key markets in the U.S., Europe and Japan.
This strategic acquisition combines Nihon Kohden’s established expertise in EEG systems with Ad-Tech’s specialized electrodes, strengthening the company’s ability to support comprehensive epilepsy care. To realize Nihon Kohden’s Long-term Vision, BEACON 2030, the company aims to provide optimal care across more of the patient and care giver’s journey. This collaboration helps support these solutions for patients in acute neurocritical care situations, preserving function and enabling precision with intraoperative neuromonitoring (IONM) and enhancing usefulness of patient data using its analytics and digital health solutions (DHS).
ARCHIMED, the previous owner of Ad-Tech, will remain as a minority JV partner with Nihon Koden. Since acquiring Ad-Tech in 2020, ARCHIMED has contributed to strengthening Ad-Tech’s business foundation and sustainable growth by deep involvement in their management, including the appointment of Brian Smith as CEO. Nihon Koden and ARCHIMED will work together to drive Ad-Tech’s future global growth.
Source: Businesswire